StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) stock

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.45+0.30 (+13.95%)

Close on Nov 17, 2026Market cap $106.08MP/E –Yield –

NRX Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

NRX Pharmaceuticals's total debt was $9.16M at Dec 31, 2023. For fiscal 2023 it was $9.16M, down 13.0% from the year before. The highest annual figure on record is $10.53M in fiscal 2022.

Annual total debt

PeriodPeriod endValueChange
FY2023Dec 31, 2023$9.16M-13.0%
FY2022Dec 31, 2022$10.53M+585.4%
FY2019Dec 31, 2019$1.54M+122.6%
FY2018Dec 31, 2018$690.00K–
FY2017Dec 31, 2017$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$9.16M-13.0%
Q3 FY2023Sep 30, 2023$10.07M+555.7%
Q2 FY2023Jun 30, 2023$12.69M+1739.4%
Q1 FY2023Mar 31, 2023$12.19M–
Q4 FY2022Dec 31, 2022$10.53M–
Q4 FY2019Dec 31, 2019$1.54M–
Q4 FY2018Dec 31, 2018$690.00K–
Q4 FY2017Dec 31, 2017$0–

More NRX Pharmaceuticals figures

See a number that looks wrong?